2 results
DEF 14A
MLYS
Mineralys Therapeutics Inc
9 Apr 24
Definitive proxy
7:15am
The following table presents summary information regarding the total compensation that was awarded to, earned by, or paid to the named executive officers for services rendered during the years ended December 31, 2023 and 2022:
Name and Principal Position | Year | Salary ($)(1) | Bonus ($)(2) | Option Awards ($)(3) | Stock Awards ($)(4) | Non-Equity Incentive Plan Compensation ($)(5) | All Other Compensation ($)(6) | Total ($) | ||||||||||||||||||||||||||||||||||||||||||
Jon Congleton | 2023 | 517,000 | — | 4,579,482 | — | 245,575 | 13,200 | 5,355,257 | ||||||||||||||||||||||||||||||||||||||||||
Chief Executive Officer | 2022 | 416,667 | 72,450 | — | 1,118,118 | 120,750 | 12,200 | 1,740,185 | ||||||||||||||||||||||||||||||||||||||||||
Adam Levy | 2023 | 450,000 | 21,375 | 1,533,806 | — | 171,000 | 13,200 | 2,189,381 | ||||||||||||||||||||||||||||||||||||||||||
Chief Financial Officer and Secretary (7) | 2022 | 334,926 | — | — | 483,500 | 190,900 | 7,262 | 1,016,588 | ||||||||||||||||||||||||||||||||||||||||||
David Rodman, M.D. | 2023 | 500,000 | — | 1,620,457 | — | 213,750 | 13,200 | 2,347,407 | ||||||||||||||||||||||||||||||||||||||||||
Chief Medical Officer | 2022 | 411,458 | 71,544 | 492,064 | — | 119,241 | 12,200 | 1,106,507 |
DEF 14A
MLYS
Mineralys Therapeutics Inc
9 Apr 24
Definitive proxy
7:15am
Our compensation committee generally considers the named executive officers’ contributions towards reaching our annual corporate goals. Each named executive office was eligible to receive a target annual bonus equal to a percentage of their respective annual base salaries for each year as follows:
Name | 2023 | 2022 | ||||||||||||
Jon Congleton | 50 | % | 25 | % | ||||||||||
Adam Levy | 40 | % | 40 | % | ||||||||||
David Rodman, M.D. | 45 | % | 25 | % |
- Prev
- 1
- Next